French Study Confirms Teratogenic Risks Of Valproate; Other Drugs In The Spotlight Too
Executive Summary
The risks of major congenital malformations in children born of women who took the anti-epileptic valproate have been confirmed by a new French study, which has also detected new risks with both old and more recent drugs for epilepsy and bipolar disorder.
You may also be interested in...
EMA Urged To Do Better On Valproate Risk Reduction In Pregnant Women
There were passionate testimonies from patients affected by Sanofi’s anti-epileptic drug valproate at the European Medicines Agency's first public hearing on medicines safety. There was almost full agreement among those who testified that existing risk reduction measures are not working.
EMA Picks Valproate For First Public Hearing On Safety Of Marketed Medicines
The European Medicines Agency is re-examining the use of valproate in women to address ongoing safety concerns and will hold its first ever public hearing later this year to listen directly to the experience of EU patients with these medicines.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.